 CUPERTINO, Calif., May 26, 2021 GLOBE NEWSWIRE -- Reviva Pharmaceuticals Holdings, Inc. NASDAQ: RVPH Reviva or the Company, a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system CNS, cardiovascular, metabolic, and inflammatory diseases, announced today the pricing of its upsized underwritten public offering of 8,000,000 shares of its common stock or pre-funded warrants to purchase common stock in lieu thereof and accompanying investor warrants to purchase up to 6,000,000 shares of common stock. Each share of common stock or pre-funded warrant in lieu thereof is being sold together with one investor warrant to purchase 0.75 shares of common stock at a combined effective price of 3.75. The investor warrants will be immediately exercisable at an exercise price of 4.125 per share of common stock and will expire five years from the date of issuance. The offering is expected to close on June 1, 2021, subject to customary closing conditions. In addition, Reviva has granted the underwriters a 45-day option to purchase an additional 1,200,000 shares of common stock andor investor warrants to purchase up to an additional 900,000 shares of common stock at the public offering price less discounts and commissions. 